First-in-human (FIH) dose selection is one of the most critical decisions in early drug development especially for complex, next-generation therapies. From ADCs to bispecific antibodies, today’s therapeutic modalities present unique PK/PD challenges that traditional dose selection methods don’t always address.
Join us at the Antibody Industrial Symposium in Tours on June 25th for a one-hour workshop focused on practical, model-informed strategies to optimize FIH dose selection. Whether you're in preclinical research, translational strategy, or clinical development, this session is designed to provide actionable insights that support better decision-making in early-phase studies.
Don’t miss this opportunity to sharpen your strategy and stay current with best practices in model-informed drug development.